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tNTRODUCTION
Despite the availability of potent new antifungal
gents, systemic fungal infections are on the rise and
re associated with signiﬁcant mortality. Candida and
spergillus species are the major fungal pathogens;
lthough deaths from candidiasis have declined
ince the late 1980s, those due to invasive aspergil-
osis (IA) are increasing [1-3]. Fifty to ninety per-
ent of patients with IA die despite therapy. Sus-
eptible populations are hospitalized patients and
mmunocompromised hosts, such as cancer patients
nd transplant recipients.
The clinical outcome of patients with IA is largely
ictated by the host immune status [4]. Two lines of
ost defense against aspergillus are resident macro-
hages and phagocytes [5,6]. Impaired monocyte/
acrophage function and neutropenia lasting 3 weeks
r longer adversely affect the prognosis, despite ap-
ropriate antifungal therapy. In recent years, in the
etting of stem cell transplantation, IA has become
nfrequent during pre-engraftment because peripheral
lood as the stem cell source and the use of growth
actors have reduced the duration of neutropenia. IA is
ow seen most commonly during postengraftment in
he setting of graft-versus-host disease (GVHD) in
llogeneic recipients; both GVHD and its treatment
eg, steroids) contribute to a delay in immune recon-
titution, and the prognosis in this cohort with IA is
oor [7,8]. At present, regardless of the antifungal
rug(s) used, a considerable number of transplant re-
ipients with IA succumb to the infection in view of
heir persistently compromised immune status.
Successful management of IA consists of a de-
rease in immunosuppression, optimal antifungal b
B&MTherapy, and immune restoration (eg, correction of
eutropenia with growth factors). The antifungal
rugs available for therapy of IA are listed in Table 1.
Amphotericin B, the mainstay of treatment of IA
or many decades, is associated with disappointing
utcomes (approximately one third survive) and con-
iderable toxicity [9,10]. There has been a recent surge
n the development of new antifungal drugs, including
ew formulations of older drugs, new drugs in the older
zole class, and entirely new classes of drugs with novel
argets. In the polyene class, lipid forms of amphotericin
(LipAmB) are clearly less nephrotoxic than conven-
ional amphotericin B deoxycholate (AmBD). Head-to-
ead comparative studies of AmBD and LipAmB are
carce. In the only comparative study of amphotericin
colloidal dispersion (ABCD) versus AmBD for
reatment of IA, in a limited number of patients (n 
74), nephrotoxicity was less with ABCD (25% versus
9%), but efﬁcacies were similar (52% and 51%) [11].
eviewing several open-label studies, Ostrosky-
eichner et al. [12] found better treatment response
ates with LipAmB. The aggregate efﬁcacy estimates
or LipAmB and AmBD were 49% and 32%, respec-
ively. They concluded that the superior safety proﬁle
f LipAmB and at least equivalent efﬁcacy make these
rugs preferable to AmBD for therapy of IA. Modestly
ized open-label trials and databases from compas-
ionate use with amphotericin B lipid complex or
iposomal amphotericin B against IA in different pop-
lations suggest a 40% to 50% clinical response rate
13-16]. Among LipAmB, ABCD has fallen out of
avor in view of its high rate of infusional toxicities
11]. An open-label study with ABCD for the preven-
ion of fungal infection in neutropenic patients had to
e stopped prematurely after severe infusion-related
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7ide effects [17]. Data suggest that liposomal ampho-
ericin B may have reduced nephrotoxicity and better
olerability during infusion, and dose escalations of
he drug are feasible in serious infections [18,19];
owever, it is difﬁcult to choose between the 2 lipid
orms in the absence of data from direct comparative
rials for therapy of IA. Because newer agents are
ecoming available, it is unlikely that a prospective
rial comparing the 2 drugs will ever be conducted.
Voriconazole has fared signiﬁcantly better than
mBD in the treatment of IA. Herbrecht et al. [20]
emonstrated the safety and superiority of voricon-
zole over AmBD as primary therapy of IA in a ran-
omized, unblinded trial. At week 12, good clinical
esponse was noted in 53% of voriconazole recipients
nd 32% of AmBD recipients. Also, improved survival
71% versus 58%) occurred in the voriconazole-
reated group. With this prospectively collected large
atabase, voriconazole is now considered the drug of
hoice for initial therapy of IA. It should be noted that
oriconazole was compared with AmBD and not
ipAmB. In the same study, clinical responses with
oriconazole and AmBD among allogeneic stem cell
ecipients were 32% and 13%, respectively, thus un-
erscoring the signiﬁcance of host immune status for
good outcome.
Itraconazole, with good activity against aspergil-
us, is available as a capsule, an oral suspension, and an
ntravenous formulation. The capsule formulation has
uboptimal bioavailability and is hence not recom-
ended for serious fungal infections. Although avail-
ble for treatment of aspergillosis since 1990, the drug
as not undergone rigorous evaluation. A retrospec-
ive survey of clinical practice showed 58% complete
r partial responses with itraconazole capsule as pri-
ary therapy of IA in 58 patients, most of whom were
ot severely immunocompromised [9]. Previous open-
abel studies have shown comparable response rates
ith itraconazole capsules and AmBD [21,22]. A reg-
able 1. Drugs for Invasive Aspergillosis
Polyenes
Amphotericin B deoxycholate
Amphotericin B lipid forms
Amphotericin B lipid complex; Abelcet
Liposomal amphotericin B; Ambisome
Amphotericin B colloidal dispension; Amphocil
Azoles
Voriconazole; V-fend
Itraconazole; Sporanox
Posaconazole (not FDA licensed)
Ravuconazole (not FDA licensed)
Echinocandins
Caspofungin; Cancidas
Micafungin (not FDA licensed)
Anidulafungin (not FDA licensed)
DA indicates Food and Drug Administration.men of intravenous itraconazole for 2 weeks followed
8y the oral formulation for 12 weeks was evaluated in
1 patients with pulmonary IA [23]. Forty-eight per-
ent (15 of 31 patients) had a complete or partial
esponse. Because large, randomized studies with itra-
onazole for therapy of IA are not available, this drug
s not recommended as initial therapy.
Caspofungin does not have cidal activity against
spergillus and has not been evaluated for initial ther-
py of IA. It is approved for use in IA in patients
ntolerant of or who have infections refractory to
ther antiaspergillus drugs. When caspofungin was
sed as salvage therapy, 40 (45%) of 90 patients had a
omplete or partial response [24,25].
Hence, at present, voriconazole is the drug of
hoice for initial therapy of IA. LipAmB has not been
valuated as well as voriconazole, and on the basis of
everal open-label studies, LipAmBmay be considered
s a secondary option for initial therapy when vori-
onazole cannot be used. Caspofungin is not a drug
or initial therapy of IA. Investigational drug classes
nclude allylamines, nikkomycins, sordarins, and prad-
micins.
Expansion in the antifungal armamentarium has
shered in several management issues for which evi-
ence-based answers are lacking. Table 2 lists several
elevant questions; some of the critical questions are
iscussed.
ORICONAZOLE VERSUS LIPAMB FOR PROVEN OR
USPECTED IA
If IA is proven or probable, therapy with voricon-
zole is preferred. In certain clinical situations, how-
ver, voriconazole may not be the optimal choice.
able 3 provides guidelines for choosing between
oriconazole and LipAmB in different clinical scenar-
os. As antimold azole prophylaxis (itraconazole or
able 2. Clinical Questions Regarding Antifungal Therapy of IA
1. What is the best drug for initial therapy for IA under
different circumstances?
2. What is the role of combination of antifungal agents?
Which drugs to combine?
When to use a combination?
3. How to monitor therapy?
4. In patients showing improvement,
What is the role of step-down therapy?
What is the duration of therapy?
5. In patients not showing improvement, what is the role of
Changing therapy to a different regimen?
Adding other agents to an existing regimen?
Increasing the dose of existing drugs?
6. What is the role of adjunct therapy?
Immunomodulation–interleukins, colony-stimulating factors,
interferons, granulocyte transfusions, or vaccines
Surgery
7. What should be the antifungal strategy for those with a
history of IA who are about to become immunosuppressed
(eg, awaiting transplantation or cancer chemotherapy)?
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Antifungal Therapy in Invasive Aspergillosis
Boriconazole) becomes commonplace, breakthrough
spergillosis with potential azole resistance or break-
hrough zygomycosis may occur [26-29]. Several in-
titutions have reported breakthrough zygomycosis
nd other fungal infections in stem cell recipients
eceiving voriconazole as empiric therapy or prophy-
axis. Thus, in the setting of mold-active azole pro-
hylaxis, treatment of IA or other mold infections
ith an azole is not optimal; in such patients, LipAmB
ould be appropriate.
When histopathology of the biopsy specimen re-
eals hyphal forms suggestive of mold infection, as-
ergillus and zygomyces are the primary consider-
tions; according to morphology, the pathogen needs
o be identiﬁed before the empiric drug choice is made
ecause zygomyces are voriconazole resistant. Both
spergillosis and zygomycosis have similar clinical
resentations, and, not infrequently, the histology
annot distinguish the 2 pathogens. Informing the
athologist about the possibility of zygomycosis is
elpful because the growth in culture is improved if
he tissue is not ﬁnely sliced during specimen process-
ng. If zygomyces and aspergillus are strong possibil-
ties, then LipAmB is appropriate as empiric therapy
gainst both pathogens. Less commonly, fusariosis or
cedosporiosis may be suspected, particularly with
ositive blood cultures or skin lesions. Voriconazole is
ffective and approved for use against both fusarium
nd scedosporium [30], whereas higher-than-usual
oses of amphotericin B lipid complex may be an
lternative for fusariosis [13]. LipAmB is not effective
gainst scedosporiosis. Pathogen identiﬁcation by cul-
ure is important. Although clinically common species
f Aspergillus fumigatus and A. ﬂavus are susceptible to
oriconazole and amphotericin B, A. terreus is resis-
ant to the latter drug [31-33]. Better clinical out-
able 3. Therapy of Suspected or Proven Aspergillosis: Choosing
etween Voriconazole and LipAmB
Variable Voriconazole LipAmB
reakthrough fungal
infection (while
receiving antimold azole
prophylaxis) No Yes
yphae on histopathology
Zygomyces No Yes*
Fusarium Yes Yes*
Scedosporium Yes No
ulture*
Aspergillus terreus Yes No
Non-terreus Aspergillus sp. Yes Yes
nvasive aspergillosis with:
Normal renal status Yes Yes
Renal insufficiency Yes† No
Concomitant nephrotoxins Yes No
High-dose LipAmB.
Oral voriconazole.omes have been noted with voriconazole in A. terreus a
B&MTnfections [34]. In aspergillus-infected patients with
enal compromise or those receiving nephrotoxic
rugs, LipAmB is best avoided. The cyclodextrin ve-
icle in the intravenous formulation of voriconazole
ay accumulate in patients with renal insufﬁciency,
nd, hence, the oral formulation is preferred in such
ituations.
OMBINATION THERAPY
The fact that only about 55% patients with IA
ave a complete or partial response with voriconazole
nderscores the clear need for treatment approaches
ther than monotherapy. What about simultaneous
se of 2 or more agents? Distinction needs to be made
etween sequential therapy (one drug replacing an-
ther) and combination therapy (use of 2 or more
rugs). With the latter strategy, 2 or more drugs may
e started at the same time as the initial therapy or an
dditional drug or drugs may be added in a serial
ashion to a failing monotherapy regimen. Previous in
itro/animal model studies with amphotericin
/ﬂucytosine, amphotericin B/rifampin, and azole/ri-
ampin combinations have produced conﬂicting data
35,36]. Results of in vitro studies or animal model
ata with the combination of amphotericin B plus
zole have not been favorable [37-40], although this
ombination has frequently been used in desperate
ituations. The combination is no longer considered
ntagonistic, but no clear advantage over therapy with
ingle agent has been shown. However, when an echi-
ocandin is combined with an azole or amphotericin
, synergy is consistently noted both in vitro and in
nimal models [41-44]. Also, successfully treated cases
ith a combination of caspofungin and itraconazole or
ipAmB have been reported [45-48]. Marr et al. [49]
howed a signiﬁcant reduction in mortality with
aspofungin plus voriconazole as compared with vori-
onazole alone in a limited retrospective study of pa-
ients with aspergillosis who experienced failure of
nitial therapy with amphotericin B formulations.
verall, although the data for combination of ampho-
ericin B plus azole are not encouraging, echinocan-
in-based combinations with an azole or polyene seem
ore promising.
With supportive clinical data lacking, combina-
ion therapy should not be the initial approach for
ll patients with IA. Because combination therapy is
xpensive, requires close monitoring (liver function
ests [LFTs], calcineurin levels, and so on), and may
urn out to be detrimental, this aggressive approach
onsisting of an echinocandin-based regimen may
e reserved for situations with an anticipated poor
utcome, such as a persistent, profound neutropenic
tate, severe GVHD/high-dose corticosteroid use,
nd disseminated or cerebral aspergillosis. Con-
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8rolled clinical trials evaluating the efﬁcacy of com-
ination therapy over monotherapy are urgently
eeded.
SSESSMENT OF TREATMENT EFFICACY
Clinical and radiologic changes have been the
ain tools to assess therapy. Gradual resolution of
linical symptoms and signs is anticipated with eradi-
ation of infection. Radiograph appearance may
orsen initially before improvement; later, the abnor-
alities may remain unchanged once tissue scarring
ccurs. Recently, a noninvasive test, the serum as-
ergillus galactomannan (GM) assay, has become
vailable for diagnosis [50,51]. The sensitivity and
peciﬁcity of the test are 81% and 89%, respectively.
umerous factors inﬂuence the performance of this
ssay, including biological factors, site of infection,
spergillus species, underlying condition/immunosup-
ression, prior exposure to antifungal drugs, and pres-
nce of GM antibodies [52]. Consequently, both false-
ositive and false-negative results are not uncommon.
otably, the antibiotic piperacillin/tazobactam (Zosyn;
ederle, Pearl River, NY) may contain GM antigen,
nd its concomitant use may produce a false-positive
est [53]. Besides diagnosing IA, the GM assay has also
een used to monitor disease progression [54]. Serial
M index measurements seem necessary in most
tudies, and an increase of the GM index 1.0 over
aseline during the ﬁrst week of therapy has predicted
reatment failure. Increasing GM values suggest treat-
ent failure, whereas decreasing GM corresponds
ith a complete or partial clinical response. At
resent, more clinical experience is needed with the
spergillus GM assay to reliably use the test for diag-
ostic or prognostic purposes. Also, the serum glucan
ssay was recently licensed for diagnosis, and the poly-
erase chain reaction assay is under intense scrutiny
55,56]. Reliable data are not available for use of these
ests during therapy of IA.
HERAPY IN PATIENTS SHOWING IMPROVEMENT
For optimal outcome, appropriate antifungal
rugs combined with an improvement in host immune
tatus are essential. Defervescence and abatement of
ymptoms within 1 week of initial therapy suggest
linical improvement. Radiographic changes may
eem worsened during the ﬁrst several days of therapy
efore showing improvement. High-resolution com-
uted tomography is helpful to observe the gradual
iminution or disappearance of nodular or cavitary
esions. For patients showing clinical improvement,
herapy may be changed from intravenous voricon-
zole to the more convenient oral formulation of the
rug. The route of administration may be switched p
0rom intravenous to oral within a few days of treat-
ent initiation. In the study by Herbrecht et al. [20],
he switch from the intravenous to oral route occurred
arly, after a median of 10 days. Oral voriconazole has
xcellent bioavailability and, in comparison with the
ntravenous form, is considerably less expensive. Ini-
iating therapy with the oral formulation of voricon-
zole may be appropriate in less critically ill patients
ith intact gastrointestinal absorption. If therapy was
egun with LipAmB, then treatment may be switched
o oral itraconazole or voriconazole upon clinical im-
rovement. Completion of therapy with an azole after
nitial treatment with a polyene has become routine
nd seems safe. Although there is a theoretical con-
ern of polyene/azole antagonism due to the common
arget site of ergosterol, sequential therapy with am-
hotericin B followed by itraconazole or voriconazole
as been found to be effective [9,57]. Maintenance of
dequate serum levels is a signiﬁcant concern, partic-
larly with oral itraconazole. For this reason, the cap-
ule formulation of itraconazole is to be avoided in
erious infections, and standard doses of intravenous
traconazole or oral suspensions are acceptable. The
atter formulations in routine doses produce adequate
erum levels [58]. Routine measurements of voricon-
zole levels with either oral or intravenous formula-
ions are not necessary. Symptoms of nausea, vomit-
ng, and diarrhea due to chemotherapy, radiation, or
VHD may preclude oral therapy. Laboratory tests
or monitoring therapy include complete blood
ounts, renal status, and LFTs. LFT abnormalities
ay be due to the fungal infection, the antifungal drug
r other drugs, other opportunistic viral infections, or
VHD. Identifying the exact etiology of abnormal
FTs may be difﬁcult; thus, liver biopsy may occa-
ionally be required.
The duration of therapy is determined by the
linical and radiologic response and the patient’s un-
erlying immune status. In general, therapy is admin-
stered for at least 3 to 4 months.
HERAPY IN PATIENTS SHOWING DETERIORATION
Clinical deterioration, despite therapy, may be a
esult of impaired host factors, the pathogen, or the
rug [59]. The importance of an intact immune status
or a good outcome cannot be overemphasized. As-
ergillus may be present in large numbers, over-
helming the antimicrobial agent, or may be drug
esistant. Aspergillus terreus is inherently resistant to
olyenes in vitro, and poor clinical response has been
ocumented [31,33]. Resistance (primary or acquired)
o polyenes among non-terreus Aspergillus species has
een extremely rare, whereas in vitro/in vivo resis-
ance to triazoles, though uncommon, has been re-
orted [60-67]. The mechanism of resistance to vori-
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Antifungal Therapy in Invasive Aspergillosis
Bonazole in a clinical isolate has been elucidated [66].
ith increasing use of triazoles for prophylaxis or
herapy, the emergence of azole-resistant aspergillus
r breakthrough zygomyces infections needs close ob-
ervation [26-29]. Also, antifungal drugs may fail to
ure the infection because of inappropriate dose, fun-
istatic activity, poor absorption/distribution and me-
abolism, or drug interactions. With more drugs avail-
ble, clinicians may feel tempted to modify therapy
ooner than before. All of this needs careful consider-
tion before a therapeutic modiﬁcation is made.
Treatment modiﬁcations in patients with progres-
ive IA on monotherapy include switching from one
rug to another (sequential therapy), adding 1 or more
rugs to an existing drug, or increasing the dose of
rug. As with combination therapy, there are no con-
incing clinical data to support the use of sequential
herapy. Voriconazole has been used with reasonably
ood results (approximately 50% response) as salvage
herapy in most patients initially treated with ampho-
ericin B [57]. At present, however, because voricon-
zole is commonly used as initial therapy, progressive
A may occur despite the azole. In such cases, the
atients could theoretically be at a higher risk for
reatment failure with a polyene because the prior
zole exposure may have depleted the common target
ie, ergosterol) [68]. No clinical study, thus far, has
mplicated prior azole exposure (as prophylaxis or
herapy) as a cause for subsequent failure with a poly-
ne, but such patients may need close observation.
chinocandins have been used in a sequential fashion
ith encouraging results. The response rate with
aspofungin as salvage therapy in refractory IA was
0%. A 22% to 28% response rate was observed when
icafungin was added to a failing regimen of LipAmB
69]. In a retrospective study of salvage therapy with
oriconazole or voriconazole plus caspofungin, the
urvival rate was 35% and 65%, respectively [49].
Another strategy during progressive IA is to in-
rease the dose of drug. The dose of LipAmB may
afely be increased from 5 mg/kg to higher doses
19,70], and, likewise, the dose of caspofungin may
afely be increased; whether higher doses are more
ffective is not clear.
DJUNCT THERAPY
In the compromised host with IA, immune en-
ancement with interleukins, colony-stimulating fac-
ors, and -interferon are adjunct strategies [34]. Al-
hough supportive data from in vitro and murine
odel studies are available, clinical evidence for the
se of such expensive agents is lacking. A European
rganization for Research and Treatment of Cancer
ulticenter prospective survey involving 20 hospitalsn 8 countries concluded that the use of growth factors c
B&MTid not inﬂuence outcome in patients with IA and
nderlying hemologic malignancies [71]. Thus, rou-
ine use of these agents is not recommended. Like-
ise, an absence of clinical evidence negates the rou-
ine use of white blood cell transfusion in patients with
A.
Surgical resection may play an important adjunct
ole in patients with hemoptysis or in those with
esions close to large blood vessels, threatening hem-
rrhage. Surgery is likely to be successful with solitary
nd easily accessible lesions in patients who are surgi-
al candidates. Caillot et al. [72] documented an 84%
ure rate with a combination of medical and surgical
herapy in neutropenic patients with IA. However,
urgical resection may not be feasible in many pa-
ients. At present, the role of surgery needs to be
ndividualized. Surgery alone, however, is not ade-
uate and must always be combined with medical
herapy.
ECONDARY PROPHYLAXIS
Deep-seated foci of IA often remain after treat-
ent, and reactivation of IA during a new neutropenic
pisode and during stem cell transplantation is esti-
ated to be 30% to 50% [73]. In the past, prior IA was
onsidered a major contraindication for stem cell
ransplantation; at present, this opinion is changing
74]. In a retrospective study of 48 stem cell recipients
ith prior IA, the risk of aspergillus relapse was 33%,
nd the death rate among those with relapsed IA was
8% [75]. The study showed that patients receiving
econdary prophylaxis with absorbable or intravenous
ntifungal drugs had fewer relapses of IA than those
ho did not receive prophylaxis. There are no pro-
pective studies of secondary prophylaxis in cancer
atients or transplant recipients with prior IA. In a
mall study of 11 leukemic patients with previous
spergillosis (n  10) or candidiasis (n  2), voricon-
zole was administered as prophylaxis for 44 to 245
ays during transplantation or consolidation chemo-
herapy; none had relapse of fungal infection [73].
iven the poor outcome in patients with IA, it is
idely accepted to administer antifungal chemopro-
hylaxis to patients with prior IA who are about to
ecome neutropenic for a prolonged period or who
re about to undergo stem cell transplantation.
ONCLUSION
In summary, with the arrival of new drugs belong-
ng to old and new classes, there is renewed optimism
n the management of IA. Concomitantly, several
uestions have arisen. These issues are not just aca-
emic but are of increasing clinical importance, be-
ause more than half of patients with IA succumb to
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8his infection. Appropriate clinical data in the man-
gement of aspergillosis are urgently needed to prac-
ice evidence-based medicine. However, relevant data
re difﬁcult to generate with rapidly changing prac-
ices in the management of both transplantation and
nfection. In the absence of such evidence, manage-
ent practices will continue to vary widely among
nstitutions, frequently at great economic cost and
ncreased patient morbidity.
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